See the moon cross the Pleiades for the last time this year on July 20
If you live anywhere in the contiguous U.S. or Canada, and clear skies are forecast for early Sunday morning, July 20, then be sure to step outside after midnight and before the first light of dawn. Look low in the east-northeast sky for a slender crescent moon just four days before new phase and 23% illuminated, gracefully approaching the Pleiades star cluster. This will mark the third and final lunar occultation of the Pleiades in 2025, promising a very beautiful scene in steadily held binoculars or a small telescope.
Earlier this year, there were two other moon-Pleiades encounters. On the evening of January 9th, an 82%waxing gibbous moon temporarily hid the Pleiades for parts of the U.S., Canada and Central America and then during the overnight hours of February 5-6, a 61% waxing gibbous moon passed in front of the cluster. If you caught one, or both of the first two events (or if you didn't), make a note on your calendar to watch this final moon-Pleiades rendezvous of the year.
In this upcoming case, you will either have to stay up through the night (to await moonrise, which will occur around 1:00 a.m. local daylight time) or set your alarm for the predawn morning hours.
In addition, since the moon will be a lovely waning crescent, as opposed to a waxing gibbous in January and February, stars will disappear first along the bright lunar crescent. You'll need at least a small telescope, for binoculars probably won't be enough for following stars in the final minutes or seconds as the moon's glare, sunlit edge creeps up to them. But practically any telescope will magnify enough to do the trick. Use 50x magnification, perhaps more if your scope has a solid mount that allows easy tracking.
Stars will reappear about an hour later from behind the moon's dark limb in dramatic fashion: appearing to suddenly "pop-on" as if someone threw a switch. Here, binoculars should do fine, especially if you mount them on a tripod, provided you're watching at exactly the right moment.
In Canada's Maritime Provinces and the northeastern U.S., advancing morning twilight will be an issue, since the eastern sky will be brightening as the moon approaches the Pleiades. As a result, the disappearance of some stars will not be visible because the sky will be too bright. Nonetheless, the view in binoculars of the crescent moon sitting to the upper right of the star cluster will still make for a very pretty sight.
Farther west, the sky will be darker, but the moon and the Pleiades will be lower. This will be especially true for the far-western states and the Canadian province of British Columbia; therefore, a clear and unobstructed view toward the east-northeast is recommended.
Below are two timetables giving local circumstances for the disappearance and reappearance of the four brightest members of the Pleiades that will be occulted. The information is based in part on data generated by the International Occultation Timers Association (IOTA) and is valid for fourteen U.S., two Canadian and one Mexican city. Keep in mind, however, that many other stars not listed here will also be occulted.
If the disappearance or reappearance of a star takes place during dawn twilight, the time is provided in italic font. Also, take note that if the disappearance or reappearance of a star occurs near or soon after the start of civil twilight (roughly 40 minutes before sunrise), it is assumed that the sky would probably be too bright to easily see it. In addition, the moon might miss the star entirely. In both such cases, the time is omitted. All times are in local civil time.
Location
Electra
Alcyone
Atlas
Maia
Los Angeles
——
2:21 a.m.
——
——
Seattle
2:03 am.
2:39 a.m.
3:16 a.m.
——
Tucson
——
2:18 a.m.
——
2:07 a.m.
Denver
2:35 a.m.
3:27 a.m.
——
——
Helena
2:52 a.m.
3:36 a.m.
4:19 a.m.
——
Monterrey
2:13 a.m.
3:28 a.m.
——
2:44 a.m.
Austin
3:17 a.m.
4:26 a.m.
——
3:51 a.m.
Kansas City
3:30 a.m.
4:31 a.m.
——
4:10 a.m.
Winnipeg
3:50 a.m.
4:43 a.m.
——
—-
N. Orleans
3:16 a.m.
——
——
3:48 a.m.
Chicago
3:33 a.m.
4:41 a.m.
——
4:12 a.m.
Atlanta
4:21 a.m.
——
——
4:54 a.m.
Miami
4:15 a.m.
——
——
4:42 a.m.
Washington
4:30 a.m.
——
——
5:05 a.m.
New York
4:35 a.m.
——
——
——
Boston
4:39 a.m.
——
——
——
Montreal
4:42 a.m.
——
——
——
Location
Electra
Alcyone
Atlas
Maia
Los Angeles
2:15 a.m.
3:10 a.m.
——
——
Seattle
2:22 a.m.
3:31 a.m.
4:01 a.m.
——
Tucson
2:13 a.m.
3:04 a.m.
——
2:27 a.m.
Denver
3:21 a.m.
4:19 a.m.
——
——
Helena
3:26 a.m.
4:31 a.m.
4:56 a.m.
——
Monterrey
3:05 a.m.
3:35 a.m.
——
3:33 a.m.
Austin
4:11 a.m.
4:51 a.m.
——
4:38 a.m.
Kansas City
4:24 a.m.
5:16 a.m.
——
4:46 a.m.
Winnipeg
4:37 a.m.
——
——
——
N. Orleans
4:11 a.m.
——
——
4:43 a.m.
Chicago
4:31 a.m.
——
——
4:57 a.m.
Atlanta
5:18 a.m.
——
——
5:52 a.m.
Miami
5:03 a.m.
——
——
5:44 a.m.
Washington
—-
——
——
——
New York
——
——
——
——
Boston
——
——
——
——
Montreal
——
——
——
——
Specific times and zones of visibility
Courtesy of IOTA, detailed prediction pages are available for each of the four brightest stars — Alcyone, Atlas, Electra, and Maia. These include Universal Time (UT) disappearance and reappearance data, as well as Mercator maps showing where each occultation will be visible.
For example, from St. Louis, Missouri (in Central Daylight Time, UTC–5), Maia will disappear at 4:06 a.m. CDT and reappear at 4:51 a.m. CDT. At the moment of reappearance, the sun will be about 11 degrees below the horizon, meaning Maia should reappear in a twilight sky.
TOP TELESCOPE PICK
Want to see the moon and Pleiades together? The Celestron NexStar 8SE is ideal for beginners wanting quality, reliable and quick views of celestial objects. For a more in-depth look at our Celestron NexStar 8SE review.
In addition to the timetable, a world map (Mercator projection) is provided, showing the region where the occultation will be visible. The boundaries are in different colors. The Cyan boundaries show the curves of the occultation disappearance or reappearance at moonrise or moonset. A continuous white line marks the nighttime northern and southern limits of the occultation. A continuous blue line denotes the occultation limits occurring during twilight, while a dotted red line depicts the occultation limits occurring in daylight.
For Alcyone, the occultation takes place over much of the western U.S. For Atlas, visibility occurs over the northwest U.S., western Canada and Alaska. For Electra, visibility will be over much of the U.S. and Canada, while the occultation of Maia will be visible primarily over the central and southern U.S. and Mexico.
Joe Rao serves as an instructor and guest lecturer at New York's Hayden Planetarium. He writes about astronomy for Natural History magazine, Sky and Telescope and other publications.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
Medscape
10 minutes ago
- Medscape
Long COVID Gene Variants: A Step Toward a Diagnostic Test?
A large-scale global study has identified genetic variants that are risk factors for long COVID, a discovery that helps researchers better understand the biological systems involving the disease and one small, early step toward the elusive goal of developing a long COVID diagnostic test. International researchers with the Long COVID Host Genetics Initiative used data from 33 independent studies and 19 countries across North America, Europe, the Middle East, and Asia to analyze the genomes of nearly 16,000 patients with long COVID, representing populations from six genetic ancestries. Nearly 1.9 million controls were included in the genome-wide association study, a research method that scans complete sets of DNA to identify genetic variations associated with a specific trait or disease. Genetic variants found in the FOXP4 gene had a statistically significant risk linked to long COVID, the study, published in Nature Genetics , found. The FOXP4 gene is known to impact lung function, and its expression levels were higher in those with long COVID than in controls. In addition, the risk variants had a consistent effect across different ancestries. The researchers also found a causal relationship between a SARS-CoV-2 infection and long COVID and an additional causal risk between infections severe enough to require hospitalization and long COVID. Researchers also analyzed possible connections between variants associated with long COVID and those linked to other diseases and conditions. Scientists said the overall findings provided evidence that was consistent with long COVID research that suggests both individual genetic variants and environmental risk factors contribute to disease risk. The findings also provide genetic proof linking abnormal lung physiology and the development of long COVID, the authors concluded; however, they noted that long COVID symptoms are not only limited to lung function and may include fatigue and cognitive dysfunction as well. The study's co-author, Hanna Ollila, PhD, with the Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, underscored that the newly discovered genetic variants were not predictive for clinical tests or personal disease risk. 'The findings from our study, and from genome-wide association studies in general, tell about biological mechanisms behind a disease. This can then help to understand the disease better. For example, is it a disease neuronal, immune, metabolic, and so on?' said Ollila, who is also a researcher with the Department of Anesthesia and Center for Genomic Medicine at Massachusetts General Hospital, Boston. There are still many steps between these types of discoveries and the development of a diagnostic test, she explained, since these types of genetic variants do not function like high-impact variants such as the BRCA mutations in breast cancer. 'In other words, they do not strongly predict whether someone will develop long COVID at the individual level,' Ollila said. 'Instead, they highlight the biological systems involved in the disease. In this case, our findings point to immune pathways related to lung function.' Ollila explained that genetics can guide diagnostic development by pointing to underlying mechanisms, which may then help identify biomarkers in blood or other tissues. These biomarkers could eventually contribute to diagnostic tools, but it is a process that takes time and collaboration and often depends on progress across several fields of research including imaging and clinical phenotyping. Researchers hope that when larger sample sizes become available for bigger studies, the analyses and understanding of the correlations will become more precise, bringing more understanding and clarity on genetic risk factors, biological mechanisms, and biomarkers that could someday help with disease diagnosis. 'We are likely still several years away, and possibly even a decade or more, from having a clinically useful diagnostic test based on genetic or biological markers for long COVID,' said Ollila. 'That said, progress is accelerating thanks to the growing number of well-characterized cohorts and international collaborations. While these genetic findings are not yet ready for clinical application, they are an important step toward understanding long COVID, its relationship with other diseases, and the disease mechanisms that modulate risk for long COVID.'
Hamilton Spectator
41 minutes ago
- Hamilton Spectator
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-related) inhibitors designed to disrupt the DNA Damage Response pathway in cancer cells. Through its collaboration with Variational AI , Rakovina Therapeutics evaluated a vast chemical space of potential molecular structures using artificial intelligence to identify novel compounds designed to selectively inhibit ATR. A subset of these AI-generated candidates has been synthesized and has advanced through initial biological screening, with multiple compounds demonstrating potent ATR inhibition in nanomolar concentration range. The most promising candidates are being prioritized for further characterization and potential development. 'The progress we're seeing in the KT-5000AI program highlights the advantage of combining artificial intelligence with modern drug design,' said Dr. Mads Daugaard, Rakovina's President and Chief Scientific Officer. 'We're particularly encouraged by the number of active compounds emerging from the first wave of screening and look forward to advancing the most promising candidates through further evaluation and development.' ATR inhibitors represent a fast-growing class of oncology therapeutics, with the global ATR inhibitor market valued at approximately US $1.24 billion in 2024, expanding at a compound annual growth rate (CAGR) of nearly 17.8% through 2033, with forecasts projecting a market size of over US $5.1 billion by 2033 (source: Growth Markets Reports ). This growth is fueled by increasing validation of ATR as an oncology target, rising need for therapies addressing replication stress and DNA repair–deficient tumors, and a shift toward personalized, AI-enabled drug development. Rakovina's KT-5000AI series is well-positioned to capture value in this expanding landscape by delivering next-generation compounds with improved selectivity, potency, and therapeutic index. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at . For Further Information Contact: Michelle Seltenrich, BSc MBA Director, Corporate Development IR@ 778-773-5432
